A 52 Week Open-label Extension Trial Following the Double-blind Efficacy and Safety Study R076477-SCH-305.

NCT00668837 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

407

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Paliperidone

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.